Three developments I’m watching today: new ovarian-cancer biology, almost USD 500 million raised through two biotech IPOs, and Big Pharma’s increasingly urgent search for pipeline assets.
Ovarian Cancer Science Advances as Biotech’s Capital Machinery Starts to Reconnect
The Daily Capital Briefing — 10 August 2026
Keep reading with a 7-day free trial
Subscribe to The Billion Dollar Blindspot to keep reading this post and get 7 days of free access to the full post archives.